Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare kidney diseases.
Our lead drug candidate, ADV7103, is currently pending European marketing authorization for distal renal tubular acidosis (dRTA), a rare kidney condition that can lead to severe complications.
At Advicenne, we are committed to developing and commercializing medications that are adapted to both children and adults – because pathbreaking treatments for rare diseases should be available to patients of all ages.
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2020 Advicenne